AUPH stock

Aurinia Pharmaceuticals Inc (AUPH) support and resistance · P/E 28, rev $283.1M

Aurinia Pharmaceuticals Inc (AUPH) is a biotechnology company listed on US.

This page maps Aurinia Pharmaceuticals Inc (AUPH) support and resistance from cached range and valuation — not a live tape and not a trade alert.

Latest reported AUPH revenue for 2025-12-31 was $283.1M. Net income was $287.2M. Revenue was up 372.8% from 2024-12-31 to 2025-12-31. AUPH currently screens at market cap $1.03B and trailing P/E 28.1.

AUPH currently screens at market cap $1.03B and trailing P/E 28.1. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.

A new AUPH 8-K or 10-Q can move the levels that matter more than a drawing on a chart.

Not investment advice. Use the AUPH quote page for the session range and the stock page for the full model.

Not investment advice.

Full AUPH analysis